Tecleab Okubai Gebregiorgis | Blood Pressure Monitoring | Research Excellence Award

Published on by Biotechnology Scientist

Mr. Tecleab Okubai Gebregiorgis | Blood Pressure Monitoring | Research Excellence Award

Orotta College of Medicine and Health Sciences | Eritrea

Mr. Tecleab Okubai Gebregiorgis is an emerging nursing researcher whose scholarly contributions demonstrate strong potential for impactful advancement in clinical nursing science, particularly in resource-limited settings. With a portfolio of 10 publications, 30 citations, and an h-index of 3 according to his Scopus profile, his research reflects a clear focus on patient-centered care, nursing practice improvement, gerontechnology, and public health challenges in underserved populations. He has contributed as both first author and co-author to peer-reviewed studies addressing critical issues such as pain management knowledge among nursing students, determinants of oral hygiene practices, psychometric validation of medication adherence scales for cancer patients, and clinical risk factors associated with postoperative delirium in cardiac surgery patients. His recent scholarly activities include systematic reviews, cross-sectional studies, and participation in international research presentations, demonstrating methodological versatility and global engagement. His work further extends to geriatric hypertension management, including home blood pressure monitoring practices and accuracy assessment in older adults-an increasingly important area in chronic disease control. Mr. Gebregiorgis also contributes to scientific dissemination through involvement in article editing, academic seminars, and departmental research initiatives. His research consistently addresses real-world health concerns, integrates evidence-based practice, and supports better clinical decision-making in low-resource contexts. With a strong foundation in clinical expertise and academic scholarship, coupled with a developing international research footprint, Mr. Tecleab Okubai Gebregiorgis shows strong suitability for the Research Excellence Award, reflecting both achievement and promising future impact in nursing science and global health research.

Citation Metrics (Scopus)

1000

500

100

50

0

Citations
30

Documents
10

h-index
3

Citations
Documents
h-index

Featured Publications

Adverse drug reactions among patients admitted to Eritrean hospitals: prevalence, causes and risk factors – a prospective analysis of 5848 patients

International Journal of Pharmacovigilance 2 (1), 1-7
Cited by: 11 | Year: 2017

Final-semester nursing students’ knowledge and attitude regarding pain management in resource-limited settings

International Journal of Africa Nursing Sciences 18, 100542
Cited by: 9 | Year: 2023

Level of oral hygiene practice and its association with socio-demographic characteristics among middle school students in low-income countries

Int J Oral Dent Health 8 (143), 10.23937
Cited by: 7 | Year: 2022

Association of postoperative delirium with hypotension in critically ill patients after cardiac surgery: a prospective observational study

Journal of Cardiothoracic Surgery 19 (1), 476
Cited by: 1 | Year: 2024

Level of Oral Hygiene Practices and its Association with Socio-Demographic Characteristics Among Middle School Students in Low Income Countries

Cited by: 1 | Year: 2021

Terin Adali | Tissue Engineering | Excellence in Research Award

Published on by Biotechnology Scientist

Prof. Dr. Terin Adali | Tissue Engineering | Excellence in Research Award

Faculty of Medicine at  Girne American University | Cyprus

Prof. Dr. Terin Adalı is a leading scholar in biomedical engineering whose scientific contributions span biomaterials, tissue engineering, drug delivery, biosensors, and polymer science, supported by a Scopus record of 392 citations, 25 documents, and an h-index of 12. Her research focuses on the synthesis, modification, and biocompatibility assessment of natural and synthetic polymers-including silk fibroin, chitosan, polyethylene glycol derivatives, and gellan gum-based systems-for regenerative medicine and therapeutic applications. She has extensively explored silk fibroin as a non-thrombogenic biomaterial, developing advanced hydrogels, injectable matrices, and composite scaffolds with applications in cartilage regeneration, ocular therapy, and sustained drug release. Her studies on PEG–DNA complexes, nanoparticle-encapsulated anticancer agents, and antibiotic-loaded biomaterials have contributed to improved targeted delivery and enhanced cellular outcomes. She has also developed polymer-based electrochemical biosensors for disease detection and micro/nanoparticles for biomedical imaging and cancer therapy. Her publications in high-impact journals demonstrate excellence in material characterization, spectroscopic analysis, cell viability assays, hemocompatibility studies, and the integration of AI-driven modeling techniques for medical diagnostics. She has contributed significantly to the understanding of scaffold–cell interactions, natural polymer reinforcement, and biodegradable material performance under physiological conditions. Her recent work includes advanced hydrogels for macular degeneration treatment and predictive models for osteoporosis using CT/MRI-based deep learning. Through her extensive scientific output, interdisciplinary collaborations, and role in shaping biomedical materials research, Prof. Dr. Terin Adalı has established a strong international presence and continues to advance innovative biomaterial technologies with impactful clinical potential.

Profiles : Scopus | Google Scholar

Featured Publications

Adali, T., Kalkan, R., & Karimizarandi, L. (2019). The chondrocyte cell proliferation of a chitosan/silk fibroin/egg shell membrane hydrogels. International Journal of Biological Macromolecules, 124, 541–547. (Cited by: 50)

Adalı, T., & Uncu, M. (2016). Silk fibroin as a non-thrombogenic biomaterial. International Journal of Biological Macromolecules, 90, 11–19. (Cited by: 50)

Yilmaz, E., Adali, T., Yilmaz, O., & Bengisu, M. (2007). Grafting of poly(triethylene glycol dimethacrylate) onto chitosan by ceric ion initiation. Reactive and Functional Polymers, 67(1), 10–18. (Cited by: 43)

Bahramzadeh, E., Yilmaz, E., & Adali, T. (2019). Chitosan-graft-poly(N-hydroxy ethyl acrylamide) copolymers: Synthesis, characterization and preliminary blood compatibility in vitro. International Journal of Biological Macromolecules, 123, 1257–1266. (Cited by: 40)

Adali, T., & Yilmaz, E. (2009). Synthesis, characterization and biocompatibility studies on chitosan-graft-poly(EGDMA). Carbohydrate Polymers, 77(1), 136–141. (Cited by: 40)

 

Jiyuan Ke | Cancer research | Best Researcher Award

Published on by Biotechnology Scientist

Mr. Jiyuan Ke | Cancer research | Best Researcher Award

Investigator at Hefei Comprehensive National Science Center, China

Dr. Jiyuan Ke is a distinguished structural biologist and cancer researcher whose career spans over two decades of impactful contributions to protein science and cancer therapeutics. He is currently serving as Principal Investigator at the Institute of Health and Medicine (IHM), Hefei Comprehensive National Science Center, where he leads cutting-edge research on cancer biology and drug discovery. His extensive body of work has focused on elucidating the structural and functional mechanisms of proteins and protein complexes with critical roles in cancer and other human diseases, emphasizing translational research for targeted and immunotherapeutic treatments.

Profile

Scopus

Education

Dr. Ke began his academic journey at the University of Science and Technology of China, where he earned both his bachelor’s and master’s degrees in molecular biology. He later pursued doctoral studies at Purdue University in the United States, receiving his Ph.D. in Biophysics and Biochemistry in 2004. His graduate research focused on the structure-function relationships of metabolic enzymes and viral proteins, laying a strong foundation for his later endeavors in structural biology.

Experience

Upon earning his doctorate, Dr. Ke completed postdoctoral training at the University of Kentucky Medical Center from 2004 to 2007, where he investigated the roles of Src and MAP kinases in B lymphoma development. He then joined the Van Andel Institute as a Scientist (2007–2016), where he conducted seminal work on the structural biology of various signaling proteins, including folate receptors, AMPK kinases, and Wnt signaling modulators. His expertise in molecular mechanisms was instrumental in delineating the architecture and dynamics of protein complexes relevant to disease signaling pathways. From 2016 to 2021, Dr. Ke transitioned into pharmaceutical research, holding positions at NewLink Genetics and H3 Biomedicine Inc. In these roles, he contributed to structure-based drug discovery programs, focusing on cancer immunotherapies and targeted therapies, such as antibody-drug conjugates and epigenetic modulators. Since 2022, as a Principal Investigator at IHM, Dr. Ke has continued his commitment to advancing basic cancer research and therapeutic innovation.

Research

Dr. Ke’s research interests lie at the intersection of structural biology, cancer signaling, and drug discovery. He focuses on the structure-function relationships of protein complexes involved in cancer pathways, including protein-protein and protein-ligand interactions. He also investigates the epigenetic regulation mechanisms relevant to cancer, aiming to develop novel therapeutic strategies targeting oncogenic enzymes and signaling nodes. His translational work bridges the gap between molecular insights and therapeutic applications, contributing to the development of new anti-cancer agents.

Awards

Throughout his career, Dr. Ke has received accolades and recognition for his research excellence. While specific awards are not listed here, his nomination for this honor reflects his influence in both academic and pharmaceutical research communities. His work is widely respected and frequently cited, with a current H-index of 27 and over 4,000 citations, underscoring the scientific impact of his research contributions.

Publications

Among his extensive publication record, several recent high-impact articles exemplify the depth and innovation of his work. Notable publications include:

  1. Zhao J et al., 2025 – p38 MAPK–mediated upregulation of claudin-3 and claudin-4 by gemcitabine contributes to chemoresistance in ovarian cancer (International Journal of Biochemistry & Cell Biology; accepted). This article underscores chemoresistance mechanisms and was cited by 3 studies.

  2. Jin Y et al., 2024 – Structural and biochemical characterization of a nucleotide hydrolase from Streptococcus pneumonia (Structure). This study advanced microbial enzymology and was cited by 7 articles.

  3. Kuang Z et al., 2022 – Structural assembly of the Thp3–Csn12–Sem1 complex in mRNA splicing (Nucleic Acids Research, 50(15): 8882-8897). This work has been cited by 10 publications.

  4. Brawn RA et al., 2020 – Aminopyrazole derivatives as FGFR2/3 inhibitors (ACS Med Chem Lett, 12(1):93–98), cited by 12 articles.

  5. Wang J et al., 2020 – Structure of the platelet glycoprotein Ib receptor with Agkisacucetin (Blood), featured as the cover article and cited by 25 articles.

  6. Xue L et al., 2020 – Oligomeric structures of YoeB–YefM complex (Nucleic Acids Research, 48(18):10527–10541), cited by 18 studies.

  7. Yao S et al., 2020 – Small molecule inhibition of CPS1 through an allosteric pocket (Cell Chem Biol, 27(3):259–268.e5), with 22 citations.

Conclusion

In conclusion, Dr. Jiyuan Ke exemplifies the caliber of a visionary scientist who seamlessly integrates structural biology with drug discovery to confront the complexities of cancer. His journey from academic laboratories to translational industry research and back to a leadership role in national science illustrates his adaptability, rigor, and enduring commitment to medical advancement. As a prolific researcher, dedicated mentor, and innovative thinker, Dr. Ke continues to shape the future of cancer therapeutics through his structural insights and collaborative impact. His nomination for this award is a recognition not only of his past achievements but also of his ongoing potential to transform cancer research and treatment.